ストックスクリーナーアプリを入手
75.51
0.39%
0.29
アフターアワーズ：
75.51
前日終値:
$75.22
開ける：
$75.73
24時間の取引高:
594.12K
Relative Volume:
0.47
時価総額：
$3.70B
収益：
-
当期純損益:
$-38.99M
株価収益率:
-25.20
EPS:
-2.9966
ネットキャッシュフロー:
$-24.94M
1週間 パフォーマンス:
+2.94%
1か月 パフォーマンス:
+2.44%
6か月 パフォーマンス:
+53.63%
1年 パフォーマンス:
+69.15%
1日の値動き範囲:
$74.34
$76.25
1週間の範囲:
$72.96
$78.78
52週間の値動き範囲:
$36.93
$80.99
Soleno Therapeutics Inc Stock (SLNO) Company Profile
名前
Soleno Therapeutics Inc
セクター
電話
650-213-8444
住所
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
SLNO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
75.51 | 3.70B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-05 | 再開されました | Stifel | Buy |
| 2024-12-02 | 繰り返されました | Robert W. Baird | Outperform |
| 2024-12-02 | 繰り返されました | Stifel | Buy |
| 2024-09-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-10 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-05 | 開始されました | Piper Sandler | Overweight |
| 2024-01-23 | 開始されました | Stifel | Buy |
| 2023-11-21 | 再開されました | Guggenheim | Buy |
| 2020-09-29 | 開始されました | Guggenheim | Buy |
| 2020-01-10 | 開始されました | Craig Hallum | Buy |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2018-02-13 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Soleno Therapeutics Inc (SLNO) 最新ニュース
Soleno Therapeutics Holds Annual Stockholders Meeting - TipRanks
Transcript : Soleno Therapeutics, Inc.Shareholder/Analyst Call - marketscreener.com
Trading (SLNO) With Integrated Risk Controls - news.stocktradersdaily.com
Soleno Therapeutics’ SWOT analysis: vykat xr launch propels stock amid rare disease market potential - Investing.com India
Stifel maintains Soleno Therapeutics stock Buy rating, $108 target - Investing.com
Stifel maintains Soleno Therapeutics stock Buy rating, $108 target By Investing.com - Investing.com India
EMA validates Soleno’s application for Prader-Willi syndrome treatment - Yahoo Finance
(SLNO) Trading Report - news.stocktradersdaily.com
Soleno Therapeutics seeking regulatory approval in treatment of PWS - Yahoo Finance
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Friday - marketscreener.com
Cantor Fitzgerald maintains Overweight on Soleno Therapeutics stock By Investing.com - Investing.com South Africa
Soleno Application for Hyperphagia Treatment in Patients with Prader-Willi Syndrome Gets European Validation - marketscreener.com
Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR - Insider Monkey
Soleno seeks EU approval for Prader-Willi syndrome treatment - Investing.com Australia
Soleno seeks EU approval for Prader-Willi syndrome treatment By Investing.com - Investing.com Canada
Soleno Therapeutics' (SLNO) MAA for PWS Treatment Validated by EMA | SLNO Stock News - GuruFocus
Soleno Therapeutics Announces Submission and EMA Validation - GlobeNewswire
Soleno's PWS Drug VYKAT Advances in Europe After Recent FDA ApprovalKey Details for Investors - Stock Titan
BCE Inc: Stock Forecast & Analysis - The Globe and Mail
Buy AT&T or Verizon Stock if Market Volatility Resurges? - The Globe and Mail
Cantor Fitzgerald maintains Overweight on Soleno Therapeutics stock - Investing.com Australia
Soleno Therapeutics to Participate in Upcoming June Conferences - GlobeNewswire
Lowe’s Stock Uptrend Can Continue for These 2 Reasons - The Globe and Mail
Rare Disease Leader Soleno Therapeutics Secures Speaking Slots at Major Healthcare Conferences - Stock Titan
Piper Sandler maintains $145 target on Soleno Therapeutics stock - Investing.com Australia
Soleno reports positive VYKAT XR results for Prader-Willi syndrome By Investing.com - Investing.com South Africa
Piper Sandler maintains $145 target on Soleno Therapeutics stock By Investing.com - Investing.com Canada
Soleno reports positive VYKAT XR results for Prader-Willi syndrome - Investing.com Australia
Soleno Therapeutics (SLNO) Reports Promising Vykat XR Study Resu - GuruFocus
Soleno Therapeutics (SLNO) Reports Promising Vykat XR Study Results | SLNO Stock News - GuruFocus
Soleno Therapeutics Presents Positive Clinical Data for VYKAT™ XR at the 2025 Pediatric Endocrine Society Annual Meeting - Nasdaq
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants wi - The Manila Times
VYKAT XR Clinical Data Shows Major Improvements in Prader-Willi Syndrome Symptoms | SLNO Stock News - Stock Titan
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Company News for May 19, 2025 - The Globe and Mail
Northern Trust Corp Buys 34,309 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025 - GlobeNewswire
New Clinical Data Shows VYKAT XR Improves Body Mass and Behavior in Prader-Willi Syndrome Patients - Stock Titan
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 - GlobeNewswire
SLNO FY2025 EPS Estimate Decreased by Cantor Fitzgerald - Defense World
Is Soleno Therapeutics (SLNO) the Best Performing Healthcare Stock to Buy Now? - Insider Monkey
11 Best Performing Healthcare Stocks to Buy Now - Insider Monkey
Got $3,000? 2 Artificial Intelligence (AI) Stocks to Buy and Hold for the Long Term - The Globe and Mail
Soleno Therapeutics Inc (SLNO) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):